Viewing nowIbandronate Sodium Hydrate Tablets (Ibandronic Acid)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Joah Pharmaceutical Co., Ltd.

MFDS item code 201205941 · Approved 2012.06.27 · Insurance code 644602670
Treatment of osteoporosis in postmenopausal women
Used for the treatment of osteoporosis in postmenopausal women.
Take 1 tablet once a month, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (other than water), or other oral medications or dietary supplements (including calcium): - This medicine must be swallowed with plenty of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Mineral water may reduce the absorption of this medicine, so take it with plain water. - To avoid esophageal ulcers, do not chew or suck the tablet. If a patient forgets to take the medicine on the scheduled dosing day - If 8 days or more remain until the next scheduled dosing day, take 1 tablet the morning after realizing that a dose was missed, and thereafter take 1 tablet each month on the originally scheduled dosing day. - If 7 days or fewer remain until the next scheduled dosing day, take 1 tablet on the next scheduled dosing day, and thereafter take 1 tablet each month on the originally scheduled dosing day. - Do not take 2 tablets in the same week. Patients whose dietary intake is inadequate should take calcium or vitamin D supplements. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary in patients with mild or moderate renal impairment with a creatinine clearance of 30mL/min or higher. Use of this medicine is not recommended in patients with a creatinine clearance below 30mL/min because clinical experience is insufficient. Older adults No dose adjustment is necessary.
Efficacy and safety have not been studied in children 18 years of age or younger.
This medication should not be administered to certain patients. For example, it should not be used in patients who are allergic to this drug or any of its components, patients with untreated hypocalcemia, patients who cannot sit or stand upright for more than 60 minutes, patients with esophageal disorders that prevent food from passing easily, and patients with genetic conditions such as lactose intolerance. For patients with severe renal impairment, this medication should be administered with caution. While taking this medication, side effects such as dyspepsia, nausea, abdominal pain, diarrhea, headache, myalgia, arthralgia, and rash may occur. Occasionally, gastrointestinal issues resembling influenza symptoms, esophagitis, or esophageal ulcers may appear and, rarely, allergic reactions such as dizziness, angioedema, and urticaria have also been reported. It is important to take this medication with calcium and vitamin D, and patients should remain upright for at least 60 minutes after taking it to reduce esophageal irritation. Additionally, this medication may irritate the gastric mucosa, so caution is advised for patients with gastritis or esophageal diseases. Patients undergoing dental treatment or with issues related to the jawbone should have an oral examination prior to taking this medication, and excessive dental treatments should be avoided. Serious bone issues such as osteonecrosis of the jaw or osteonecrosis of the external auditory canal may also arise while taking this medication, hence caution is needed. This medication may have impaired absorption when taken with food, milk, calcium supplements, antacids, etc., therefore, it is advisable not to consume other food or drugs for at least one hour after taking it. Women who are pregnant or breastfeeding should not use this medication, and safety and efficacy in children under 18 years have not been established. In the case of overdose, symptoms such as gastrointestinal discomfort, esophagitis, and hypocalcemia may occur, and immediate consultation with a healthcare professional is advised if these symptoms appear. Finally, this medication should be kept out of reach of children, and unused medication should be disposed of properly to prevent environmental contamination.
Indigestion, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle spasms, musculoskeletal pain, musculoskeletal rigidity, dysphagia, vomiting, esophageal ulcer, stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial edema, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylactic reaction, shock, exacerbation of asthma, allergic reaction, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical subtrochanteric fracture, intertrochanteric femur fracture, abnormal sensations in the eyes, asthenia, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, and kept at room temperature between 1 and 30 degrees Celsius. Storing it this way helps maintain the drug's efficacy for a longer period.
White or nearly white, rectangular film-coated tablet
1 T/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowIbandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Joah Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.